Defilade Capital Management, L.P.
Defilade Capital Management, L.P. reported 39 holdings worth US$747M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Defilade Capital Management, L.P. reported 39 holdings worth US$747M as of Jun 30, 2026. Largest: Eli Lilly And Company, Pfizer, Inc. and Veeva Systems Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 39
- Value as reported
- US$747M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Eli Lilly And Company | 39,086 | US$46.9M | 6.3% |
| Pfizer, Inc. | 1.77M | US$42.7M | 5.7% |
| Veeva Systems Inc. | 237K | US$42M | 5.6% |
| Biomarin Pharmaceutical Inc. | 682K | US$39M | 5.2% |
| Ptc Therapeutics, Inc. | 434K | US$35.4M | 4.7% |
| Baxter International Inc. | 1.46M | US$31.1M | 4.2% |
| Insmed Incorporated | 282K | US$30M | 4.0% |
| Zimmer Biomet Holdings, Inc. | 317K | US$27.3M | 3.7% |
| Insulet Corporation | 177K | US$26.9M | 3.6% |
| Thermo Fisher Scientific Inc | 51,934 | US$26M | 3.5% |
| Abbott Laboratories | 286K | US$25.9M | 3.5% |
| Solventum Corporation | 316K | US$24.4M | 3.3% |
| Elanco Animal Health Incorporated | 864K | US$21.3M | 2.8% |
| Agios Pharmaceuticals, Inc. | 547K | US$20.3M | 2.7% |
| Envista Holdings Corporation | 726K | US$19.1M | 2.6% |
| Revolution Medicines, Inc. | 82,827 | US$15.5M | 2.1% |
| Icu Medical, Inc. | 106K | US$15.5M | 2.1% |
| Cogent Biosciences, Inc. | 393K | US$15.2M | 2.0% |
| Lantheus Holdings, Inc. | 133K | US$14.7M | 2.0% |
| Ocular Therapeutix, Inc. | 1.49M | US$14.6M | 2.0% |
| Eledon Pharmaceuticals, Inc. | 3.53M | US$13.9M | 1.9% |
| Tyra Biosciences, Inc. | 377K | US$12M | 1.6% |
| Olema Pharmaceuticals, Inc. | 925K | US$11.6M | 1.5% |
| Oric Pharmaceuticals, Inc. | 1.05M | US$11.3M | 1.5% |
| Larimar Therapeutics, Inc. | 3.67M | US$11.2M | 1.5% |
| Globus Medical, Inc. | 140K | US$11M | 1.5% |
| Enovis Corporation | 532K | US$11M | 1.5% |
| Evommune, Inc. | 793K | US$10.5M | 1.4% |
| Teleflex Incorporated | 80,118 | US$10.2M | 1.4% |
| Denali Therapeutics Inc. | 392K | US$10.1M | 1.3% |
| Glaukos Corporation | 66,519 | US$9.3M | 1.2% |
| Staar Surgical Company | 322K | US$9.24M | 1.2% |
| Pacs Group, Inc. | 216K | US$9.2M | 1.2% |
| Crinetics Pharmaceuticals, Inc. | 239K | US$8.96M | 1.2% |
| Black Diamond Therapeutics, Inc. | 1.67M | US$3.1M | 0.41% |
| Becton, Dickinson And Company | 0 | US$0 | 0.00% |
| Biogen Inc. | 0 | US$0 | 0.00% |
| Biohaven Ltd. | 0 | US$0 | 0.00% |
| Dexcom, Inc. | 0 | US$0 | 0.00% |
| Henry Schein, Inc. | 0 | US$0 | 0.00% |
| Integer Holdings Corporation | 0 | US$0 | 0.00% |
| Intuitive Surgical, Inc. | 0 | US$0 | 0.00% |
| Neurocrine Biosciences, Inc. | 0 | US$0 | 0.00% |
| Nuvalent, Inc. | 0 | US$0 | 0.00% |
| Tandem Diabetes Care, Inc. | 0 | US$0 | 0.00% |
| Align Technology, Inc. | 0 | US$0 | 0.00% |
| Ascendis Pharma A/s | 0 | US$0 | 0.00% |
Source
View original at SEC
Related